新诊断的高级别星形细胞瘤患者在标准放疗和替莫唑胺治疗下淋巴细胞亚群的连续变化。

Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide.

机构信息

Oncology Division, Departments of Medicine, Washington University in St Louis, St Louis, MO, 63110, USA.

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

出版信息

J Neurooncol. 2017 Nov;135(2):343-351. doi: 10.1007/s11060-017-2580-z. Epub 2017 Jul 29.

Abstract

The immune system plays a significant role in cancer prevention and outcome. In high grade astrocytomas (HGA), severe lymphopenia is associated with shortened survival due to tumor progression. This study was performed to quantify serial changes in lymphocyte subsets in HGA following standard radiation (RT) and temozolomide (TMZ). Adults (KPS >60, HIV negative) with newly diagnosed HGA scheduled to receive concurrent RT and TMZ and adjuvant TMZ were eligible. Blood was collected before beginning concurrent RT/TMZ and at weeks 6, 10, 18, and 26, and 3 months after completing adjuvant TMZ. Lymphocyte subsets were analyzed by flow cytometry. Twenty patients (70% glioblastoma, median age 53, 50% male, 80% Caucasian) who enrolled from January 2014 to August 2014 were followed until April 2016. Baseline dexamethasone dose was 0.5 mg/day and 15% had absolute lymphocyte counts (ALC) <1000 cells/mm before starting RT/TMZ. However, 75% developed lymphopenia with ALC <1000 cells/mm after completion of RT/TMZ. NK cells, B cells and all T lymphocytes subsets dropped significantly after concurrent RT/TMZ and remained depressed for the 48 weeks of observation. The CD4+/CD8+ ratio was not affected significantly during follow-up. Severe lymphopenia involving all subsets occurred early in treatment and remained present for nearly 1 year. To our knowledge, this is the first report of serial trends in lymphocyte subsets following standard RT and TMZ for HGA.

摘要

免疫系统在癌症的预防和结果中起着重要作用。在高级别星形细胞瘤(HGA)中,由于肿瘤进展导致严重的淋巴细胞减少与生存时间缩短有关。本研究旨在定量分析 HGA 患者在接受标准放疗(RT)和替莫唑胺(TMZ)治疗后淋巴细胞亚群的系列变化。符合条件的患者为新诊断为 HGA、计划接受同步 RT 和 TMZ 及辅助 TMZ 治疗的成年人(KPS>60,HIV 阴性)。在开始同步 RT/TMZ 前以及在第 6、10、18 和 26 周以及完成辅助 TMZ 后 3 个月采集血液。通过流式细胞术分析淋巴细胞亚群。2014 年 1 月至 2014 年 8 月期间,20 例患者(70%为胶质母细胞瘤,中位年龄 53 岁,50%为男性,80%为白种人)入组并随访至 2016 年 4 月。基线地塞米松剂量为 0.5mg/天,15%的患者在开始 RT/TMZ 前的绝对淋巴细胞计数(ALC)<1000 个/ mm3。然而,75%的患者在完成 RT/TMZ 后出现 ALC<1000 个/ mm3的淋巴细胞减少症。在同步 RT/TMZ 后,NK 细胞、B 细胞和所有 T 淋巴细胞亚群显著下降,并在观察的 48 周内持续下降。在随访期间,CD4+/CD8+比值没有明显变化。所有亚群的严重淋巴细胞减少症早期出现,并持续近 1 年。据我们所知,这是首次报道 HGA 患者在接受标准 RT 和 TMZ 治疗后淋巴细胞亚群的系列趋势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索